"Trastuzumab emtansine" trang 1 - tải miễn phí từ tailieunhanh
Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: A case report

Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: A case report
4    48    0
Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation

Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation
12    47    1
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
9    50    1
High score of LDH plus dNLR predicts poor survival in patients with HER2- positive advanced breast cancer treated with trastuzumab emtansine

High score of LDH plus dNLR predicts poor survival in patients with HER2- positive advanced breast cancer treated with trastuzumab emtansine
13    36    3
Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
8    31    1
Real-world effectiveness of posttrastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: A retrospective observational study (KBCSGTR 1917)

Real-world effectiveness of posttrastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: A retrospective observational study (KBCSGTR 1917)
12    61    1
Determination of cellular processing rates for a Trastuzumab-Maytansinoid antibody-drug conjugate (ADC) highlights key parameters for ADC design

Determination of cellular processing rates for a Trastuzumab-Maytansinoid antibody-drug conjugate (ADC) highlights key parameters for ADC design
12    83    0
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis
7    25    1
Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: A systematic review and meta-analysis

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: A systematic review and meta-analysis
15    70    0
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review
8    84    1
The SystHERs registry: An observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

The SystHERs registry: An observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer
11    45    1
Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: A report of two cases

Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: A report of two cases
5    49    1
Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
8    55    1